nach oben

Erschienen in:

25.10.2016 | Original Article

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study

verfasst von: Takuya Hirai, Keigo Ikeda, Maki Fujishiro, Hiroshi Tsushima, Kunihiro Hayakawa, Satoshi Suzuki, Ayako Yamaguchi, Kazuhisa Nozawa, Shinji Morimoto, Yoshinari Takasaki, Hideoki Ogawa, Kenji Takamori, Naoto Tamura, Iwao Sekigawa

Erschienen in: Clinical Rheumatology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The study aims to confirm the feasibility of new oral triple combination therapy using methotrexate (MTX), mizoribine (MZR), and tacrolimus (TAC) in patients with rheumatoid arthritis (RA) by in vitro and clinical analyses. Triple therapy with a combination of MTX, MZR, and TAC was used for an in vitro study with osteoclasts and a prospective clinical study in order to show the efficacy of these agents against refractory RA. In particular, low-dose TAC or MZR was added to treat 14 patients with RA that was resistant to MTX + MZR or MTX + TAC dual therapy. The combination of three pharmacological agents showed statistically significant differences to reduce differentiation induction and activity of osteoclasts compared with single and double agents. In clinical use, triple therapy showed a statistically significant difference in the improvement of Disease Activity Score-28-erythrocyte sedimentation rate and the Simple Disease Activity Index score at around 8 months. Additionally, the serum matrix metalloproteinase-3 level significantly decreased. No patients dropped out because of adverse effects. Based on this in vitro and prospective clinical study, oral triple therapy might be effective against refractory RA. Furthermore, this therapy might be safe and economical for clinical practice.

Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777. doi:10.1136/bmj.i1777 CrossRefPubMedPubMedCentral

Nagashima M, Matsuoka T, Saitoh K, Koyama T, Kikuchi O, Yoshino S (2006) Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 24(3):260–267PubMed

Kitahama M, Nakajima A, Inoue E, Taniguchi A, Momohara S, Yamanaka H (2013) Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Mod Rheumatol 23(4):788–793. doi:10.1007/s10165-012-0745-3 CrossRefPubMed

de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78. doi:10.1136/annrheumdis-2011-201162 CrossRefPubMed

Ogasawara M, Tamura N, Kageyama M, Onuma S, Kusaoi M, Toyama S, Sekiya F, Matsudaira R, Nawata M, Tada K, Matsushita M, Kempe K, Amano H, Morimoto S, Yamaji K, Takasaki Y (2012) Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clin Rheumatol 31(2):251–257. doi:10.1007/s10067-011-1810-6 CrossRefPubMed

O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(5):1164–1170. doi:10.1002/art.10228 CrossRefPubMed

Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, Investigators T (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64(9):2824–2835. doi:10.1002/art.34498 CrossRefPubMedPubMedCentral

Ishikawa H (1999) Mizoribine and mycophenolate mofetil. Curr Med Chem 6(7):575–597PubMed

Hughes SE, Gruber SA (1996) New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 36(12):1081–1092CrossRefPubMed

10.

Ichinose K, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, Kamachi M, Arima K, Tamai M, Nakamura H, Ida H, Kawakami A, Tsukada T, Ueki Y, Eguchi K (2010) Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med 49(20):2211–2218CrossRefPubMed

11.

Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I (2016) Mizoribine synchronized methotrexate therapy should be considered when treating rheumatoid arthritis patients with an inadequate response to various combination therapies. Intern Med (in press)

12.

Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M et al (1992) The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 176(3):751–760CrossRefPubMed

13.

Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66(4):807–815CrossRefPubMed

14.

Aramburu J, Garcia-Cozar F, Raghavan A, Okamura H, Rao A, Hogan PG (1998) Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol Cell 1(5):627–637CrossRefPubMed

15.

Miyazaki M, Fujikawa Y, Takita C, Tsumura H (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 26(2):231–239. doi:10.1007/s10067-006-0287-1 CrossRefPubMed

16.

Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekiguchi N, Nishi E, Ogawa H, Tsuzaka K, Takeuchi T (2009) Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int 29(4):431–436. doi:10.1007/s00296-008-0833-z CrossRefPubMed

17.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. doi:10.1002/art.27584 CrossRefPubMed

18.

Nozawa K, Fujishiro M, Kawasaki M, Kaneko H, Iwabuchi K, Yanagida M, Suzuki F, Miyazawa K, Takasaki Y, Ogawa H, Takamori K, Sekigawa I (2009) Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther 11(6):R174. doi:10.1186/ar2863 CrossRefPubMedPubMedCentral

19.

Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806. doi:10.1186/ar1740 CrossRefPubMedPubMedCentral

20.

Yan TZ, Wu XQ, Rong L (2016) A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: a randomized study. SAGE Open Med 4:2050312116643672. doi:10.1177/2050312116643672 CrossRefPubMedPubMedCentral

21.

Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N (2012) Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27(4):1467–1472. doi:10.1093/ndt/gfr484 CrossRefPubMed

22.

Kanasaki Y, Tomonari M, Sasaki H, To H (2012) Chronopharmacology of mizoribine in collagen-induced arthritis rats. J Pharmacol Sci 120(2):112–120CrossRefPubMed

23.

Choe JY, Park KY, Park SH, Lee SI, Kim SK (2013) Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther 15(1):R26. doi:10.1186/ar4162 CrossRefPubMedPubMedCentral

24.

Kukar M, Petryna O, Efthimiou P (2009) Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics 3:443–457PubMedPubMedCentral

25.

Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60(7):1895–1905. doi:10.1002/art.24567 CrossRefPubMed

Titel: The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study
verfasst von: Takuya Hirai
Keigo Ikeda
Maki Fujishiro
Hiroshi Tsushima
Kunihiro Hayakawa
Satoshi Suzuki
Ayako Yamaguchi
Kazuhisa Nozawa
Shinji Morimoto
Yoshinari Takasaki
Hideoki Ogawa
Kenji Takamori
Naoto Tamura
Iwao Sekigawa
Publikationsdatum: 25.10.2016
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 1/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-016-3458-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Rich but poor: life in the Roman period with extreme rheumatoid arthritis

Status of rheumatology practice and professional training courses in rural areas of China—an ILAR project

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study

Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population

Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis

The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in rheumatoid arthritis patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin